Axon Enterprise (NASDAQ:AXON) Rating Reiterated by JMP Securities

Axon Enterprise (NASDAQ:AXON)‘s stock had its “market outperform” rating reiterated by stock analysts at JMP Securities in a research report issued on Wednesday, Benzinga reports. They presently have a $375.00 target price on the biotechnology company’s stock. JMP Securities’ price objective indicates a potential upside of 7.38% from the stock’s current price.

Several other equities analysts also recently commented on AXON. Jefferies Financial Group initiated coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective on the stock. JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Bank of America assumed coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective for the company. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research note on Wednesday. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $348.08.

Axon Enterprise Trading Up 18.4 %

Shares of NASDAQ:AXON traded up $54.24 during trading on Wednesday, reaching $349.24. The company’s stock had a trading volume of 3,366,760 shares, compared to its average volume of 517,121. The stock has a market capitalization of $26.36 billion, a PE ratio of 102.12, a price-to-earnings-growth ratio of 6.59 and a beta of 0.95. Axon Enterprise has a 12 month low of $175.59 and a 12 month high of $367.95. The company has a current ratio of 2.91, a quick ratio of 2.55 and a debt-to-equity ratio of 0.37. The firm’s 50 day simple moving average is $296.14 and its two-hundred day simple moving average is $294.62.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the previous year, the business earned $0.80 EPS. The company’s quarterly revenue was up 34.5% on a year-over-year basis. On average, research analysts predict that Axon Enterprise will post 2.35 EPS for the current fiscal year.

Insider Activity

In related news, Director Jeri Williams sold 308 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total value of $95,501.56. Following the completion of the transaction, the director now owns 1,607 shares in the company, valued at approximately $498,282.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, President Joshua Isner sold 44,000 shares of the stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $309.96, for a total value of $13,638,240.00. Following the sale, the president now owns 275,843 shares in the company, valued at $85,500,296.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 308 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the transaction, the director now directly owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The disclosure for this sale can be found here. Insiders have sold 89,447 shares of company stock valued at $27,684,677 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DAVENPORT & Co LLC acquired a new position in Axon Enterprise in the fourth quarter valued at approximately $219,000. Stratos Wealth Partners LTD. increased its holdings in Axon Enterprise by 7.7% in the fourth quarter. Stratos Wealth Partners LTD. now owns 5,342 shares of the biotechnology company’s stock valued at $1,380,000 after buying an additional 382 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Axon Enterprise by 26.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,500 shares of the biotechnology company’s stock worth $904,000 after acquiring an additional 742 shares during the period. Bleakley Financial Group LLC boosted its stake in shares of Axon Enterprise by 15.5% during the 4th quarter. Bleakley Financial Group LLC now owns 1,587 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 213 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at about $39,907,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.